HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine

Overview

Journal Pediatrics

Specialty Pediatrics

Date 2023 Jun 15

PMID 37317810

Authors

Yi Zeng

Anna-Barbara Moscicki

Heide Woo

Chiu-Hsieh Hsu

Troy J Kemp

Ligia A Pinto

Eva Szabo

Eileen Dimond

Julie Bauman

Vikrant V Sahasrabuddhe

H-H Sherry Chow

Affiliations

Soon will be listed here.

Abstract

Objectives: A single dose of human papillomavirus (HPV) vaccine would simplify logistics and reduce costs of vaccination programs worldwide. We conducted a phase IIa trial to determine the stability of HPV type-specific antibody responses after a single dose of the nonavalent HPV vaccine, Gardasil9.

Methods: Two hundred-and-one healthy 9 to 11-year-old girls and boys were enrolled at 2 centers in the United States to receive a prime dose of the nonavalent vaccine at baseline, a delayed dose at month 24, and an optional third dose at month 30. Blood samples were collected to measure HPV type-specific antibodies at baseline and at 6, 12, 18, 24, and 30 months after the prime dose. The primary outcomes were serum HPV16 and HPV18 antibody responses.

Results: In both girls and boys, geometric mean concentrations of HPV16 and HPV18 antibodies increased at 6 months, declined between months 6 to 12, and then remained stable and high (at 20- and 10-times those at baseline for HPV16 and HPV18, respectively) throughout months 12, 18, and 24 (prebooster) visits. Both HPV16 and HPV18 antibody responses demonstrated anamnestic boosting effect at 30-months after the delayed (24-month) booster dose.

Conclusions: A single dose of the nonavalent HPV vaccine induced persistent and stable HPV16 and HPV18 antibody responses up to 24 months. This study contributes important immunogenicity data to inform feasibility of the single dose HPV vaccination paradigm. Further research is needed to assess the long-term antibody stability and individual clinical and public health benefit of the single dose schedule.

Citing Articles

ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV.

Pinto-Santini D, Jalil E, Fernandes G, Hilaire G, Kolevic L, Cabello R BMC Cancer. 2025; 25(1):151.

PMID: 39871186 PMC: 11771066. DOI: 10.1186/s12885-025-13551-z.

Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia.

Daniels V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, Thobari J, Durand N PLoS One. 2024; 19(11):e0310591.

PMID: 39570910 PMC: 11581242. DOI: 10.1371/journal.pone.0310591.

Reproducibility Assessment of Enzyme-Linked Immunosorbent Assays to Detect Anti-HPV16 L1-Specific IgG1, IgG3, IgA, and IgM Antibodies.

Matsui K, Hempel H, Shelton G, Ocampo R, Kemp T, Pan Y Vaccines (Basel). 2024; 12(10).

PMID: 39460275 PMC: 11511443. DOI: 10.3390/vaccines12101108.

WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58.

Kemp T, Panicker G, Eklund C, Nie J, Wang Y, Beddows S NPJ Vaccines. 2024; 9(1):165.

PMID: 39256440 PMC: 11387505. DOI: 10.1038/s41541-024-00949-2.

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials.

Whitworth H, Mounier-Jack S, Choi E, Gallagher K, Howard N, Kelly H Vaccine X. 2024; 19:100486.

PMID: 38873638 PMC: 11169951. DOI: 10.1016/j.jvacx.2024.100486.

References

Safaeian M, Porras C, Pan Y, Kreimer A, Schiller J, Gonzalez P . Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013; 6(11):1242-50. PMC: 7605443. DOI: 10.1158/1940-6207.CAPR-13-0203. View

Whitworth H, Gallagher K, Howard N, Mounier-Jack S, Mbwanji G, Kreimer A . Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. 2019; 38(6):1302-1314. DOI: 10.1016/j.vaccine.2019.12.017. View

Watson-Jones D, Changalucha J, Whitworth H, Pinto L, Mutani P, Indangasi J . Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. Lancet Glob Health. 2022; 10(10):e1473-e1484. PMC: 9638030. DOI: 10.1016/S2214-109X(22)00309-6. View

Agosti J, Goldie S . Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med. 2007; 356(19):1908-10. DOI: 10.1056/NEJMp078053. View

Zeng Y, Moscicki A, Sahasrabuddhe V, Garcia F, Woo H, Hsu C . A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol. BMC Cancer. 2019; 19(1):290. PMC: 6444524. DOI: 10.1186/s12885-019-5444-4. View

Baisley K, Kemp T, Kreimer A, Basu P, Changalucha J, Hildesheim A . Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial. Lancet Glob Health. 2022; 10(10):e1485-e1493. PMC: 9638025. DOI: 10.1016/S2214-109X(22)00306-0. View

Romanowski B, Schwarz T, Ferguson L, Ferguson M, Peters K, Dionne M . Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother. 2014; 10(5):1155-65. PMC: 4896558. DOI: 10.4161/hv.28022. View

Porras C, Sampson J, Herrero R, Gail M, Cortes B, Hildesheim A . Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. Vaccine. 2021; 40(1):76-88. PMC: 8759448. DOI: 10.1016/j.vaccine.2021.11.041. View

Dessy F, Giannini S, Bougelet C, Kemp T, David M, Poncelet S . Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer.... Hum Vaccin. 2008; 4(6):425-34. DOI: 10.4161/hv.4.6.6912. View

10.

Ruiz-Sternberg A, Moreira Jr E, Restrepo J, Lazcano-Ponce E, Cabello R, Silva A . Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Res. 2017; 5:63-74. PMC: 5887018. DOI: 10.1016/j.pvr.2017.12.004. View

11.

Dauner J, Pan Y, Hildesheim A, Kemp T, Porras C, Pinto L . Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes. 2012; 26(2):73-80. PMC: 3319198. DOI: 10.1016/j.mcp.2012.01.002. View

12.

Kreimer A, Sampson J, Porras C, Schiller J, Kemp T, Herrero R . Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. J Natl Cancer Inst. 2020; 112(10):1038-1046. PMC: 7566548. DOI: 10.1093/jnci/djaa011. View

13.

Robbins H, Kemp T, Porras C, Rodriguez A, Schiffman M, Wacholder S . Comparison of antibody responses to human papillomavirus vaccination as measured by three assays. Front Oncol. 2014; 3:328. PMC: 3888946. DOI: 10.3389/fonc.2013.00328. View

14.

Smolen K, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G . Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012; 30(24):3572-9. DOI: 10.1016/j.vaccine.2012.03.051. View

15.

Pingali C, Yankey D, Elam-Evans L, Markowitz L, Valier M, Fredua B . National Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(35):1101-1108. PMC: 9472778. DOI: 10.15585/mmwr.mm7135a1. View

16.

Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J . Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 2022; 41(1):236-245. PMC: 9792650. DOI: 10.1016/j.vaccine.2022.11.044. View

17.

Pinto L, Dillner J, Beddows S, Unger E . Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine. 2018; 36(32 Pt A):4792-4799. PMC: 6050153. DOI: 10.1016/j.vaccine.2017.11.089. View

18.

Barnabas R, Brown E, Onono M, Bukusi E, Njoroge B, Winer R . Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022; 1(5):EVIDoa2100056. PMC: 9172784. DOI: 10.1056/EVIDoa2100056. View